2 hours ago
Ozempic shaper Novo Nordisk said connected Tuesday it is suing arch US rival Eli Lilly complete “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.
The Danish pharmaceuticals heavyweight complained that nan US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against little doses of Novo Nordisk’s medicines.
Eli Lilly’s ads “deceptively (presented) those results arsenic impervious of broad, product-level superiority while burying aliases omitting captious objective context”, Novo Nordisk said.
Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide.
The competing narcotics are a financial windfall for each of nan pharmaceutical companies.
“As caller and much effective curen options go available, group merit meticulous accusation that reflects nan latest technological grounds and helps them make informed attraction decisions,” said John F Kuckelman, Novo Nordisk’s wide counsel.
“Healthcare companies person a work to support their nationalist claims meticulous and existent – ineffective, fine-print disclaimers do not hole nan misleading belief created by awesome nationalist campaigns.”
The target of nan Danish group’s wrath is an advertizing run that was “aired during recent, wide viewed world sporting broadcasts and connected TikTok and Facebook, causing wide confusion”, it said.
Eli Lilly responded to its rival’s accusations pinch a connection saying that nan proceedings which underpins its advertising, known arsenic Surmount-5, is “the only direct, head-to-head randomised objective proceedings comparing tirzepatide and semaglutide successful nan discourse of weight management”.
An Eli Lilly spokesperson added that “rather than competing connected nan merits of its products, Novo is asking a tribunal to forestall Lilly from communicating nan results of this trial. We firmly guidelines by our advertizing campaign.”
Anti-obesity treatments mimic a hormone secreted by nan intestines, GLP-1.
They tin beryllium utilized for weight nonaccomplishment and/or to dainty type 2 diabetes, nan astir communal shape of nan disease.
